Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke [Phase 2]

View source ↗

Summary

Pfizer terminated its Phase 2 trial evaluating CP-101,606 for acute stroke. The update provides the termination status but does not report trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• CP-101,606 (CP-101,606)

Snippet

Sponsor: Pfizer | Conditions: Stroke | Phase 2 | Status: TERMINATED